Grant ID RP220313
Awarded On February 16, 2022
Title Imaging Metabolic Reprogramming in Prostate Cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Federica Pisaneschi
Cancer Sites Prostate
Contracted Amount $915,256.35
Award Transfer Information

Previous Organization: The University of Texas M.D. Anderson Cancer Center

Expended at Previous Organization: $134,743.65

Lay Summary

Patients with advanced prostate cancer (PCa) receive anti-androgens (Enzalutamide) as the first line of treatment. Unfortunately, many patients develop resistance, and the disease relapses with aggressive histology and metastatic castrate-resistant (mCRPC) phenotype. Treatment options for mCRPC patients are limited and continue to pose a significant oncological challenge.

There is growing recognition that alterations in cell metabolism and reprogramming of metabolic pathways are key drivers of PCa aggressiveness, progression and eventual resistance to therapy. We propose to develop metabolic imaging to target treatment strategies of different metabolic sub-types of PCa. Two dysregulated meta...

Read More